Aeglea: Why Are Aeglea BioTherapeutics Shares Sinking Today?

Aeglea BioTherapeutics Inc (NASDAQ: AGLE) shares are plunging in reaction to the interim results from the Phase 1/2 trial of pegtarviliase for Classical Homocystinuria and strategic alternatives process. Classical Homocystinuria is a rare inherited methionine metabolism disorder resulting in elevated homocysteine levels. Results from the first two cohorts (0.15 mg/kg and 0.45 mg/kg, respectively) showed pegtarviliase lowered homocysteine levels compared to baseline. Also Read: Full story available on Benzinga.com